Clinical trial · no report yet · Phase 1
HEROEX-1
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- NCT06521554 ↗
- Recruiting
- Nuvalent Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1a/1b Study of the Selective Tyrosine Kinase Inhibitor NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Locally Advanced Solid Tumor; Metastatic Solid Tumor
- Interventions
- NVL-330
- Arms
- Phase 1a dose escalation · Experimental
- Phase 1b dose expansion · Experimental
- Enrollment
- 200 (estimated)
- Primary outcomes
- Recommended Phase 2 Dose (RP2D)
- Maximum Tolerated Dose (MTD)
- Incidence and severity of Treatment Emergent Adverse Events (TEAEs)
- Sponsor
- Nuvalent Inc.
- Start
- Jul 18, 2024
- Primary completion
- Jan 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06521554 · updated Oct 20, 2026